Redirecting to https://ir.clovisoncology.com/investors-and-news/news-releases/press-release-details/2020/Rubraca-Rucaparib-Approved-in-the-US-as-Monotherapy-Treatment-for-Patients-with-BRCA12-Mutant-Metastatic-Castration-Resistant-Prostate-Cancer-mCRPC-Who-Have-Been-Treated-with-Androgen-Receptor-Directed-Therapy-and-a-Taxane-Based-Chemotherapy/default.aspx...

Click here if your browser doesn't automatically take you to this page.